Authors: J.F. MIRJOLET, M. HILLAIRET DE BOISFERON, O. DUCHAMP, F. BICHAT, M. MANFREDI, P. GENNE
Oncodesign, Millennium Pharmaceuticals
Hematological malignancies are rare malignant disorders accounting for 6.2% of all deaths from cancers. For decades, chemotherapy was the only available approach for patients with advanced hematological malignancies but the effectiveness of such therapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. The emergence of targeted agents in clinic gives new efficient alternatives to patient in failure of reference treatments. Modeling human disease in rodents has become essential in biomedical research for the optimization of preexisting therapeutic modalities and the testing of novel ones.
In this study, we investigated the antitumor activity of MLN8054 (Aurora A kinase inhibitor), Glivec® (multikinase inhibitor) and Mabthera® (monoclonal antibody against CD20) in such hematological malignancies disseminated in mice.